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A multicenter randomized open-label long-term sequential deferi-
prone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential
DFP-DFO) performed in patients with thalassemia major (TM) was ret-
rospectively reanalyzed to assess the variation in the left ventricular
ejection fraction (LVEF) [1].
Serial observations of LVEF over 3 years, in the same patient, were retro-
spectively assessed in 99 patients with TM during the sequential DFP-DFO
multicenter randomized open-label trial [1]. A generalized estimating equa-
tion (GEE) model was used to demonstrate changes in mean LVEF over
time [2].
The regression coefﬁcient of treatment suggested that the DFP-alone
group showed a statistically signiﬁcant increase in mean LVEF over time
(coefﬁcient 0.97, 95% CI (0.51; 1.44), P-value <0.0001).
These ﬁndings suggest that long-term treatment with DFP-alone can sig-
niﬁcantly enhance LVEF over time. These ﬁndings agree with a survival
analysis reporting a substantial decline in cardiac deaths during recent
years, related to the switching of high-risk patients from DFO to chelation
regimens that include the oral chelator DFP [3–5].
Oral chelation treatment has improved greatly adherence and manage-
ment of patients with TM [6,7].
The improvement of the LVEF after 1-year DFP treatment has been
reported [8–11].
However, the effects of DFP on LVEF after long-term treatment have not
been fully investigated.
This letter reports a retrospective survey performed on patients with
TM, previously enrolled in a long-term randomized open-label trial carry-
ing ahead in Italy on the behalf of the Italian Society for the Study of
Thalassaemia and Haemoglobinopathies (SoSTE) [1]. Ninety-nine out of
213 patients enrolled in the sequential DFP-DFO trial underwent long-
term echocardiographic study of LVEF measured at baseline and every
12 months over three consecutive years (Fig. 1). Among these, 39 and
60 received sequential DFP (75 mg/kg for 4 days/week)–DFO (50 mg/kg
for 3 days/week) or DFP-alone (75 mg/kg for 7 days/week) treatment,
respectively (Table I).
The hematological and clinical ﬁndings at enrollment are shown in Table I.
No differences were observed at baseline between the two randomized
groups. Particularly, the main ﬁndings of body iron overloading, expressed
as serum ferritin at baseline, liver iron concentration (LIC), baseline LVEF
<55%, and total number of blood transfusions were not statistically signiﬁ-
cantly different (Table I). Moreover, although baseline LVEF appears unlike
between the two groups (Fig. 1), this was not statistically signiﬁcantly differ-
ent (P-value 5 0.10, Table I).
The DFP-alone group showed statistically signiﬁcant increase over time in
mean LVEF in comparison with sequential DFO-FP treatment (coefﬁcient
0.97, 95% CI (0.51; 1.44), P-value <0.0001).
Furthermore, the regression coefﬁcient of treatment suggested that there
was a statistically signiﬁcant difference in mean LVEF between the two
treated groups favoring the sequential group (coefﬁcient 2.36, 95% CI (0.02;
4.71), P-value 5 0.047, but this last treatment did not show a statistically
signiﬁcant variation of mean LVEF over time (coefﬁcient 20.34, 95% CI
(21.09; 0.39), P-value 5 0.359). These ﬁndings suggest that DFP-alone
treatment signiﬁcantly improves LVEF over time.
As it is well known, the main cause of death in patients with TM remains
mechanical and electrophysiological myocardial dysfunction, the incidence of
which ranges from 11.4% to 15.1% [12].
Several survival analyses have suggested a substantial decline in cardiac
deaths over recent years, which are related to the tendency to switch high-
risk patients from subcutaneous DFO to chelation regimens that include the
oral chelator DFP [3,4].
Pennell et al. [9] suggested that, during an RCT of over 1 year, in a com-
parison of DFO to DFP, LVEF increased signiﬁcantly in the DFP-treated
group (3.1% vs. 0.3% absolute units; P 5 0.003) whilst DFP in combination
with DFO raised absolute LVEF by 2.6% [10]. Moreover, Pennel et al. [11]
showed that these changes in LVEF (3.1% vs. 2.6%), measured by cardiac
magnetic resonance (CMR) during DFP-alone or combination, were associ-
ated with risk reduction for development of heart failure over 12 months of
46.4% or 25.5%, respectively.
However, although the use of CMR is spreading [13], its availability is so
far limited, constituting worldwide for many centers, where thalassemia is
common, one of the main crucial issue for the right management of patients
Figure 1. Estimated proﬁles from the ﬁtted GEE model for the DFP-alone group
and the sequential DFP-DFO group. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
TABLE I. Baseline Findings in the 99 Patients Included in the Retrospective
Cohort Study
Findings DFP group Sequential group P-value
No. patients (99) 60 39
Females (%) 22 (36.66) 21 (53.84) 0.25
Age in years 31 ± 7.52 31 ± 8.66 0.96
Hgb, (g/L) 9.24 ± 0.87 9.32 ± 0.68 0.78
ALT, (IU/L) 49.73 ± 37.88 38.27 ± 45.97 0.43
LIC, mg/g/dw 2946.03 ± 2026.56 2351.08 ± 2234.03 0.38
Total blood transfusion,
mL/kg/year
8716.172 ± 2111.04 8268.02 ± 2561.87 0.34
Mean ferritin, mg/L 1664.21 ± 846.62 1717.54 ± 497.79 0.84
Baseline LVEF
<55% (n)
52 ± 2.19 (6) 50.66 ± 3.05 (3) 0.47
Baseline LVEF 59.25 ± 4.25 60.89 ± 5.78 0.10
Mean starting age
of DFO, years
5.75 ± 4.34 5.03 ± 4.61 0.46
Splenectomy (%) 33(55) 27 (69.23) 0.26
Cirrhosis (%) 54 (90.00) 38 (97.43) 0.16
Arrhythmia (%) 49 (81.66) 35 (89.74) 0.31
HCV-RNA positive (%) 42 (70.00) 30 (76.92) 0.51
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with TM [14]. Instead, worldwide availability of echocardiography is surely
greater. Furthermore, several recent studies have shown the excellent inter-
observer and intraobserver reproducibility of echocardiographic evaluation
on LVEF [15,16]. This has been evaluated as similar to that of cardiac mag-
netic resonance (CMR), even in patients with TM [17]. Finally, Otterstad
et al. [18] suggested that 2-D echocardiography measurements of LVEF is
more accurate and reproducible if the determination is performed, as in our
study, by single operator.
The most likely explanation for the improvement in LVEF function using
DFP could be due to its cardioprotective effect on mitochondrial function as
it was suggested in cultured, iron-loaded heart cells, even at concentrations
below the iron-mobilizing effect [19], although, the exact mechanism of this
effect remains unknown [11].
In conclusion, this retrospective survey of the sequential DFP-DFO trial
data suggests that the long-term administration of DFP signiﬁcantly enhan-
ces LVEF over time, as determined by echocardiography. However, because
of limitations related to the design of this study, these ﬁndings should be
conﬁrmed in a prospective randomized clinical trial.
Methods
Ecocardiographic measurement of LVEF. LVEF was measured by single
operator with echocardiography by dividing the stroke volume by the end-diastolic
volume in each patient (Vivid S5, Gems Ultrasound, Tirat Carmel, Israel).
Statistical analysis. The GEEs [2] model was used to evaluate possible
changes in mean LVEF over time between the sequential DFP-DFO treat-
ment and the treatment with DFP alone. This approach was implemented in
the ‘‘xtgee’’ procedure presented as part of the Stata 11 software (Stata-
Corp, College Station, TX). All of the statistical analyses were performed at
the Department of Mathematical and Statistical Science ‘S. Vianelli’, Univer-
sity of Palermo (Italy).
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